FR09C0037I2 - ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE - Google Patents

ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE

Info

Publication number
FR09C0037I2
FR09C0037I2 FR09C0037C FR09C0037C FR09C0037I2 FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2
Authority
FR
France
Prior art keywords
japanese encephalitis
attenuated
vero cell
vaccine
encephalitis virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0037C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research filed Critical CJ Corp
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE Active FR09C0037I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
FR09C0037I1 FR09C0037I1 (en) 2009-09-25
FR09C0037I2 true FR09C0037I2 (en) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (en) 1997-08-28 2009-08-14 ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE

Country Status (15)

Country Link
US (1) US6309650B1 (en)
EP (2) EP1025209B1 (en)
JP (1) JP4161017B2 (en)
KR (1) KR100314404B1 (en)
CN (1) CN1142271C (en)
AU (1) AU748730B2 (en)
CA (1) CA2301000C (en)
DE (2) DE69837211T2 (en)
DK (2) DK1604685T3 (en)
ES (2) ES2382946T3 (en)
FR (1) FR09C0037I2 (en)
MY (1) MY129773A (en)
NL (1) NL300391I2 (en)
NZ (1) NZ503522A (en)
WO (1) WO1999011762A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (en) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst Japanese encephalitis virus vaccine
KR20010032699A (en) * 1998-10-05 2001-04-25 무따이 마사히꼬 Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
DK2251419T3 (en) * 1999-04-22 2012-07-02 Us Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
BR0210628A (en) * 2001-06-29 2004-08-10 Becton Dickinson Co Intradermal release of vaccines and genetic therapeutic agents via microcannula
JP2007068401A (en) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst West nile virus vaccine
EP1718738A2 (en) * 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
CN100340596C (en) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 Recovery of polycarbonate / acrylonitrile-butadiene-styrene copolymer and method for reclaiming same
ATE412737T1 (en) * 2005-04-11 2008-11-15 Crucell Holland Bv VIRUS CLEANING WITH ULTRAFILTRATION
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
KR20160003301A (en) * 2007-12-26 2016-01-08 기타사토 다이이치 산쿄 백신 가부시키가이샤 Method of producing Japanese encephalitis vaccine stably storable over long time and use of the vaccine
KR101507822B1 (en) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 Use of inactivated japanese encephalitis virus particle as adjuvant
CN102112151A (en) * 2008-07-30 2011-06-29 久光制药株式会社 Microneedle device and method for increasing the response of japanese encephalitis virus antigen with the microneedle device
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (en) * 2009-06-18 2012-06-27 대한민국 Antigen for high concentrated hemagglutination of porcine japanese encephalitis virus
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN105744952A (en) * 2013-09-14 2016-07-06 巴拉特生物技术国际有限公司 A viral vaccine and methods of manufacture thereof
CN105695424B (en) * 2015-04-01 2019-06-14 中国食品药品检定研究院 Adapted strain and its vaccine of the Japanese Encephalitis Vaccine,Live strain SA14-14-2 on human diploid cell 2BS
WO2017109225A1 (en) 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
US10881723B2 (en) * 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
JP7301811B2 (en) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー Method for Producing a Pharmaceutical Composition Containing the Immunogenic Chikungunya Virus CHIKV-DELTA 5NSP3
CN111511395B (en) 2017-11-03 2024-10-15 武田疫苗股份有限公司 Methods for inactivating Zika virus and for determining completeness of inactivation
JP2021505549A (en) 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Dika vaccine and immunogenic composition, and how to use them
CN110684747B (en) * 2018-07-06 2024-05-24 厦门大学 Method for inactivating and preserving respiratory syncytial virus
SG11202101889PA (en) * 2018-08-27 2021-03-30 Mican Tech Inc Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (en) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 Recombinant vaccinia virus
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (en) * 1988-11-10 1996-01-24 武田薬品工業株式会社 Japanese encephalitis vaccine manufacturing method
EP0562136A1 (en) 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
NZ503522A (en) 2001-06-29
EP1604685B1 (en) 2012-02-22
NL300391I1 (en) 2009-08-03
EP1025209B1 (en) 2007-02-28
AU9004798A (en) 1999-03-22
ES2382946T3 (en) 2012-06-14
JP4161017B2 (en) 2008-10-08
MY129773A (en) 2007-04-30
FR09C0037I1 (en) 2009-09-25
CN1272879A (en) 2000-11-08
DE122009000037I2 (en) 2011-06-16
EP1025209A1 (en) 2000-08-09
EP1604685A3 (en) 2006-07-05
CA2301000C (en) 2003-07-08
DK1025209T3 (en) 2007-06-25
DE69837211T2 (en) 2007-12-06
EP1604685A2 (en) 2005-12-14
CN1142271C (en) 2004-03-17
KR19990023955A (en) 1999-03-25
KR100314404B1 (en) 2002-10-12
US6309650B1 (en) 2001-10-30
DK1604685T3 (en) 2012-06-18
DE122009000037I1 (en) 2009-11-05
NL300391I2 (en) 2009-11-02
DE69837211D1 (en) 2007-04-12
WO1999011762A1 (en) 1999-03-11
CA2301000A1 (en) 1999-03-11
AU748730B2 (en) 2002-06-13
JP2001514844A (en) 2001-09-18
ES2281929T3 (en) 2007-10-01

Similar Documents

Publication Publication Date Title
FR09C0037I2 (en) ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE
GB2337755B (en) Virus vaccine
PL324906A1 (en) Vaccines against viral hepatitis of c type
PL321966A1 (en) Vaccine against viral hepatitis of b type
EP1112091A4 (en) Rapid cryobaric sterilization and vaccine preparation
HUP0003911A3 (en) Treatment of neoplasms with viruses
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
PL354090A1 (en) Peptides that block viral infectivity and methods of use thereof
DZ1706A1 (en) Hepatitis A vaccine.
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
IS5777A (en) Vaccine hepatitis B virus variants and its use
HUP9904171A3 (en) Immunogenic peptides of foot-and-mouth disease viruses
AU4529401A (en) Aids ancestral viruses and vaccines
EP1113777A4 (en) Novel hepatitis c virus peptides and uses thereof
IL143149A0 (en) Stable, attenuated rabies virus mutants and live vaccines thereof
HK1034202A1 (en) Combined vaccine against hepatitis a and hepatitisb
GB9702990D0 (en) Virus vaccine
GB9423663D0 (en) Viral preparations, immunogens, and vaccines
PT841943E (en) HERITAL VIRUSES USEFUL VIRUSES AS TUMORIDAL AGENTS AND VACCINES
AU8096998A (en) Attenuated human immunodeficiency virus vaccine
HU0400424D0 (en) Hepatitis virus vaccines
AU7276198A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
GB9816773D0 (en) Virus vectors and expression elements,their preparation and use
GB9503395D0 (en) Viral,preparations,immunogens,and vaccines
EP1229042A4 (en) Cyclic peptides and aids vaccines